Negative Antiamyloid Drug Trial: Lessons Learned Negative Antiamyloid Drug Trial: Lessons Learned

Although crenezumab was not superior to placebo in individuals who are at high risk for Alzheimer ' s disease in the API ADAD Colombia Trial, results provide important data for future studies, experts say.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news